| scholarly article | Q13442814 |
| P2093 | author name string | Stefan Beissert | |
| P2860 | cites work | Absence of T-regulatory cell expression and function in atopic dermatitis skin | Q61703521 |
| CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2 | Q74660381 | ||
| Control of intestinal inflammation by regulatory T cells | Q77291202 | ||
| The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients | Q79953485 | ||
| Fox-P3-positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium-dose UVA1 therapy | Q80379300 | ||
| Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma | Q80726300 | ||
| A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells | Q81157115 | ||
| IL-2 family of cytokines in T regulatory cell development and homeostasis | Q81826665 | ||
| Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus | Q81990288 | ||
| Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? | Q83125659 | ||
| Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice | Q83179770 | ||
| Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin | Q84307121 | ||
| Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis | Q84532300 | ||
| Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 | ||
| Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function | Q24305624 | ||
| Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro | Q24648847 | ||
| Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways | Q24653432 | ||
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
| Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 | ||
| The inhibitory cytokine IL-35 contributes to regulatory T-cell function | Q28258462 | ||
| DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27 | Q28285583 | ||
| Foxp3+ regulatory T cells maintain immune homeostasis in the skin | Q28509891 | ||
| CCR6 regulates the migration of inflammatory and regulatory T cells | Q28511778 | ||
| A function for interleukin 2 in Foxp3-expressing regulatory T cells | Q28590646 | ||
| How regulatory T cells work | Q29614262 | ||
| Mechanisms of foxp3+ T regulatory cell-mediated suppression | Q29615842 | ||
| Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self | Q29619194 | ||
| The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production | Q29619536 | ||
| Epigenetic control of the foxp3 locus in regulatory T cells | Q33273617 | ||
| FOXP3 promoter demethylation reveals the committed Treg population in humans. | Q33320522 | ||
| Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking | Q33492305 | ||
| Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation | Q33993967 | ||
| Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance | Q34111451 | ||
| CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor | Q34116317 | ||
| IL-35-mediated induction of a potent regulatory T cell population. | Q34432872 | ||
| Interleukin 2 signaling is required for CD4(+) regulatory T cell function | Q34527240 | ||
| CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. | Q34554035 | ||
| Regulatory T cells in patients with systemic lupus erythematosus. | Q34554466 | ||
| TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells | Q34556464 | ||
| Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases | Q34615216 | ||
| Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Q34621389 | ||
| Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer | Q34729938 | ||
| Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking | Q35208814 | ||
| Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. | Q35242154 | ||
| Antigen-specific regulatory T cells--their induction and role in infection | Q35703522 | ||
| Nonredundant roles for Stat5a/b in directly regulating Foxp3 | Q35828667 | ||
| Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3. | Q35844411 | ||
| Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype | Q36059631 | ||
| Natural regulatory T cells in infectious disease | Q36078051 | ||
| Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease | Q36229433 | ||
| CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. | Q36229540 | ||
| Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration | Q36344582 | ||
| Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. | Q36403529 | ||
| A two-step process for thymic regulatory T cell development. | Q36470183 | ||
| The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells | Q36509846 | ||
| OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection | Q36537926 | ||
| T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. | Q36693820 | ||
| Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. | Q36725004 | ||
| Immune regulation and control of regulatory T cells by OX40 and 4-1BB | Q36794126 | ||
| Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells | Q36842568 | ||
| Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells | Q36843721 | ||
| The Foxp3+ regulatory T cell: a jack of all trades, master of regulation | Q37088900 | ||
| Identification of regulatory T cells in systemic lupus erythematosus. | Q37382498 | ||
| Molecular orchestration of differentiation and function of regulatory T cells | Q37390979 | ||
| Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. | Q37414801 | ||
| Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. | Q37524839 | ||
| Regulatory T cells: how do they suppress immune responses? | Q37593768 | ||
| Treg and lupus | Q37649061 | ||
| FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents | Q37828869 | ||
| Phenotypical and functional specialization of FOXP3+ regulatory T cells | Q37832385 | ||
| Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice | Q39251161 | ||
| Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. | Q40110921 | ||
| Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production | Q40165347 | ||
| An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice | Q40432672 | ||
| Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state | Q42466421 | ||
| Molecular mechanisms underlying FOXP3 induction in human T cells | Q42491664 | ||
| IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development | Q42932412 | ||
| Decrease of regulatory T cells in patients with systemic lupus erythematosus | Q42956126 | ||
| Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both. | Q43028008 | ||
| ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions | Q43140494 | ||
| Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis. | Q43274049 | ||
| CTLA-4-Ig regulates tryptophan catabolism in vivo. | Q44170968 | ||
| T regulatory cells in atopic dermatitis and subversion of their activity by superantigens | Q44853685 | ||
| Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients | Q45864185 | ||
| Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. | Q45879987 | ||
| In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity | Q45884432 | ||
| CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. | Q46019176 | ||
| Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus | Q46156032 | ||
| DNA methylation controls Foxp3 gene expression | Q46391168 | ||
| Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus | Q46521582 | ||
| Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. | Q46723121 | ||
| Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes | Q46942111 | ||
| Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. | Q47726082 | ||
| Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor | Q47740353 | ||
| Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. | Q47828390 | ||
| Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. | Q51103369 | ||
| IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. | Q51998742 | ||
| DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. | Q52924279 | ||
| Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. | Q53531553 | ||
| Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. | Q53883439 | ||
| Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. | Q54193154 | ||
| Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. | Q54537170 | ||
| Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. | Q54621895 | ||
| Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells | Q56901814 | ||
| Activation requirements for the induction of CD4+CD25+ T cell suppressor function | Q56903555 | ||
| Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells | Q56903879 | ||
| Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells | Q57184743 | ||
| Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus | Q57603266 | ||
| P433 | issue | 3 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 864-871 | |
| P577 | publication date | 2011-12-08 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Regulatory T cells: banned cells for decades | |
| P478 | volume | 132 |
| Q87093155 | Alloantigen-specific CD4(+) regulatory T cells induced in vivo by ultraviolet irradiation after alloantigen immunization require interleukin-10 for their induction and activation, and flexibly mediate bystander immunosuppression of allograft rejecti |
| Q41160055 | Cutaneous RANK-RANKL Signaling Upregulates CD8-Mediated Antiviral Immunity during Herpes simplex Virus Infection by Preventing Virus-Induced Langerhans Cell Apoptosis |
| Q45905729 | Daily intake of Jeju groundwater improves the skin condition of the model mouse for human atopic dermatitis. |
| Q43698661 | Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome |
| Q35826624 | Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy |
| Q51629879 | Ensuring dermatology's future. |
| Q28072762 | Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury |
| Q90267370 | Filaggrin null mutations are associated with altered circulating Tregs in atopic dermatitis |
| Q41080079 | Foxp3(+) regulatory T cells are expanded in severe atopic dermatitis patients. |
| Q34083589 | IL-17/Th17 pathway is activated in acne lesions |
| Q34750481 | Immunomodulatory effects of transforming growth factor-β in the liver |
| Q38026914 | Immunoregulation of skin sensitization and regulatory T cells |
| Q36354332 | Involvement of Fas/FasL pathway in the murine model of atopic dermatitis |
| Q27321721 | Ionizing radiation selectively reduces skin regulatory T cells and alters immune function |
| Q42145973 | Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities |
| Q38118882 | Milestones in photoimmunology |
| Q28072363 | New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells |
| Q30353758 | PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection. |
| Q26995751 | Regulatory T cell in stroke: a new paradigm for immune regulation |
| Q38060115 | Regulatory T cells in inflammatory bowel diseases and colorectal cancer |
| Q90454567 | The Gut Microbiome as a Major Regulator of the Gut-Skin Axis |
| Q41892056 | The expression levels of transcription factors T-bet, GATA-3, RORγt and FOXP3 in peripheral blood lymphocyte (PBL) of patients with liver cancer and their significance |
| Q63805098 | The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease |
| Q91711458 | The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics |
| Q48881731 | Treg-enriched CD4+ T cells attenuate collagen synthesis in keloid fibroblasts |
| Q28080942 | Ultraviolet-induced alloantigen-specific immunosuppression in transplant immunity |
| Q28081150 | Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease |
Search more.